REVLIMID Adverse Event: Invasive ductal breast carcinoma
REVLIMID Adverse Event: Invasive ductal breast carcinoma is one of 4,500 adverse events in the FDATracker dataset. Key details — Primary drug: REVLIMID; Product category: Drug; Primary reaction: Invasive ductal breast carcinoma.
| Primary drug | REVLIMID |
|---|---|
| Product category | Drug |
| Primary reaction | Invasive ductal breast carcinoma |
| All reactions | Invasive ductal breast carcinoma |
| Seriousness | Serious |
| Patient outcome | Recovered/Resolved |
| Patient sex | Female |
| All drugs reported | REVLIMID; REVLIMID; REVLIMID; DABIGATRAN |
| Reporter country | CA |
| Reporter type | 2 |
| Report date | 20140313 |
| Report ID | 10006223 |
$299/mo
Try FDATracker →